Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
LE135 provokes nociceptive responses and elicited thermal hyperalgesia mainly through TRPV1 channels
BAY2416964 specifically binds to AhR
can be used to prepare drugs for resisting liver cancer and stomach cancer drugs or auxiliary chemotherapy drugs
ML-18 inhibits specific 125I-BA1 (DTyr-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH2)BB6-14 binding to NCI-H1299 lung cancer cells stably transfected with BRS-3 with IC50 values of 4
whereas the MTD of docetaxel combined with MS-209 greatly reduced MCF-7/ADM tumor growth
Relugolix Catalog No.:M18801-C LE135 provokes nociceptive responses andRelugolix (TAK 385) is a potent, orally active, nonpeptidic gonadotropin releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0. 33 nM) and monkey receptor (IC50=0. 32 nM) compared with TAK 013 (HY 100209). Relugolix is used for the study of sex hormone dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al. Product information